Effects of locally administered rhBMP-2 and bisphosphonate on bone regeneration in the rat fibula

Hydroxyapatite microbeads containing BMP-2 and quercetin fabricated via electrostatic spraying to encourage bone regeneration

BACKGROUND

Hydroxyapatite (HAp) possesses osteoconductive properties, and its granular form can serve as an effective drug delivery vehicle for bone regeneration. Quercetin (Qct), a plant-derived bioflavonoid, is known to promote bone regeneration; however, its comparative and synergistic effects with the commonly used bone morphogenetic protein-2 (BMP-2) have not been investigated.

METHODS

We examined the characteristics of newly formed HAp microbeads using an electrostatic spraying method and analyzed the in vitro release pattern and osteogenic potential of ceramic granules containing Qct, BMP-2, and both. In addition, HAp microbeads were transplanted into a rat critical-sized calvarial defect and the osteogenic capacity was assessed in vivo.

RESULTS

The manufactured beads had a microscale size of less than 200 μm, a narrow size distribution, and a rough surface. The alkaline phosphatase (ALP) activity of osteoblast-like cells cultured with the BMP-2-and-Qct-loaded HAp was significantly higher than that of either Qct- or BMP-2-loaded HAp groups. The mRNA levels of osteogenic marker genes such as ALP and runt-related transcription factor 2 were found to be upregulated in the HAp/BMP-2/Qct group compared to the other groups. In micro-computed tomographic analysis, the amount of newly formed bone and bone surface area within the defect was significantly higher in the HAp/BMP-2/Qct group, followed by the HAp/BMP-2 and HAp/Qct groups, which is consistent with the histomorphometrical results.

CONCLUSIONS

These results imply that electrostatic spraying can be an efficient strategy to produce homogenous ceramic granules and that the BMP-2-and-Qct-loaded HAp microbeads can serve as effective implants for bone defect healing.

Zoledronate Bound to Ceramics Increases Ectopic Bone Volume Induced by rhBMP6 Delivered in Autologous Blood Coagulum in Rats

Autologous bone graft substitute (ABGS) containing rhBMP6 in autologous blood coagulum (ABC) with synthetic ceramics is a novel therapeutic solution for bone repair. The aim of this study was to investigate whether the application of Zoledronate (ZOL) with ABGS might enhance the properties of newly formed bone. The effect of ZOL on bone induction was tested in a rat subcutaneous implant model. ZOL bound to synthetic ceramics was added into ABGS implants, and the quantity, quality, and longevity of the induced bone were assessed by micro-CT, histomorphometry, and histology over a period of 365 days. Local use of ZOL in the ABGS implants with ceramics had no influence on the bone volume (BV) on day 14 but subsequently significantly increased BV on days 35, 50, 105, 140, and 365 compared to the control implants. Locally applied ZOL had a similar effect in all of the applied doses (2–20 µg), while its systemic use on stimulating the BV of newly induced bone by ABGS depended on the time of application. BV was increased when ZOL was applied systemically on day 14 but had no effect when applied on day 35. The administration of ZOL bound to ceramics in ABGS increased and maintained the BV over a period of one year, offering a novel bone tissue engineering strategy for treating bone defects and spinal fusions.

Core Ossification of Bone Morphogenetic Protein-2-Loaded Collagenated Bone Mineral in the Sinus

The objective of this study was to investigate in vitro release kinetics and ossification patterns of bone morphogenetic protein-2-soaked collagenated porcine bone mineral (BMP-2/CPBM) in rabbit sinuses. Release kinetics of BMP-2/CPBM was determined in vitro up to 56 days. In 16 rabbits, BMP-2/CPBM (BMP group) and CPBM alone (control group) were bilaterally grafted in both sinuses. After 4 (N = 8) and 12 (N = 8) weeks, radiographic and histologic analyses were performed. Approximately 40% of BMP-2 was released from CPBM during 3 days in vitro; release maintained at a reduced level until day 56. In vivo, new bone formation in BMP group was dominant at the center and decreased toward the borders of the sinus, while it mainly possessed close to the sinus membrane and basal bone in control group. At the center, significantly more new bone was found in BMP group compared to control group at 4 weeks (29.14% vs. 16.50%; p < 0.05). The total augmented volume of BMP group was significantly greater than control group at 4 (370.13 mm³ vs. 299.32 mm³) and 12 (400.40 mm³ vs. 290.10 mm³) weeks (p < 0.05). In conclusion, BMP-2/CPBM demonstrated a core ossification with a greater augmented volume and new bone formation in the center of the sinus compared to CPBM alone. Impact statement The center of the augmented maxillary sinus tends to show a slower and inferior new bone formation compared to the sites near the sinus membrane and basal bone. In this study, bone morphogenetic protein-2 (BMP-2) loaded onto collagenated porcine bone mineral (CPBM) resulted in a greater augmented volume and new bone formation at the center of the grafted sinus compared to CPBM alone. Therefore, BMP-2-added CPBM in maxillary sinus augmentation may potentially be beneficial to the clinicians, in terms of accelerating the new bone formation at the center area where the apical half of the implant fixture usually places.

Dental alloplastic bone substitutes currently available in Korea

As dental implant surgery and bone grafts were widely operated in Korean dentist, many bone substitutes are commercially available, currently. For commercially used in Korea, all bone substitutes are firstly evaluated by the Ministry of Health and Welfare (MOHW) for safety and efficacy of the product. After being priced, classified, and registration by the Health Insurance Review and Assessment Service (HIRA), the post-application management is obligatory for the manufacturer (or representative importer) to receive a certificate of Good Manufacturing Practice by Ministry of Food and Drug Safety. Currently, bone substitutes are broadly classified into C group (bone union and fracture fixation), T group (human tissue), L group (general and dental material) and non-insurance material group in MOHW notification No. 2018-248. Among them, bone substitutes classified as dental materials (L7) are divided as xenograft and alloplastic bone graft. The purpose of this paper is to analyze alloplastic bone substitutes of 37 products in MOHW notification No. 2018-248 and to evaluate the reference level based on the ISI Web of Knowledge, PubMed, EMBASE (1980–2019), Cochrane Database, and Google Scholar using the criteria of registered or trademarked product name.